NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
02 April 2025
| Name: | ZELDA THERAPEUTICS LIMITED (ZLD) (This company subsequently changed its name to ZELIRA THERAPEUTICS LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 28 July 2003 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to ZELIRA THERAPEUTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
This company subsequently changed its name to ZELIRA THERAPEUTICS LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now ZELIRA THERAPEUTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| ZELIRA THERAPEUTICS LIMITED | 05/12/2019 | |
| ZELDA THERAPEUTICS LIMITED | 11/10/2016 | 05/12/2019 |
| GLENEAGLE GOLD LIMITED | 11/10/2016 |
Computershare Perth
Level 17, 221 St Georges Terrace, Perth WA 6000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to Zelira Therapeutics Limited | 05/12/2019 |
The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. | 18/11/2016 |
The company is pleased to announce that it has successfully raised the maximum allowed under its prospectus offering. A total of 160,000,000 post-consolidation shares will be issued to new investors at 2.5 cents per share raising the full $4,000,000. The funds raised are to continue with pre-clinical R&D activities, fund human clinical trials and expand the management/ advisory team. | 15/11/2016 |
The company issues a second supplementary prospectus intended to be read with the prospectus dated 11 July 2016 and the supplementary prospectus lodged 11 October 2016. | 08/11/2016 |
The company lodges its Quarterly Activities Report. | 31/10/2016 |
The company lodges its Quarterly Cashflow Report. | 31/10/2016 |
The company's meeting will be held at 12.30pm (WST) on 28 November 2016 at CPS Capital Boardroom Level 45, 108 St Georges Terrace Perth WA 6000. | 28/10/2016 |
The company advises that the ASX has granted a waiver from listing rule 14.7 to the extent necessary to permit the Company to issue securities, as approved by shareholders at the general meeting held on 25 July 2016. This is purely a technical issue related to the extended timetable and does not affect any material aspect of the transaction. | 26/10/2016 |
we understand that on or about this date the company consolidated its shares 1 for 5 | 25/10/2016 |
The share consolidation has been completed. | 12/10/2016 |
On 11 October 2016, the company lodged a supplementary prospectus with the ASIC which extends the offer period by a minimum of one month. Unfortunately, due to technical issues associated with having the company re-admitted to ASX for quotations the company is required to issue the attached supplementary prospectus and extend the offer period until no earlier than the 11 November 2016. | 12/10/2016 |
name changed from Gleneagle Gold Limited | 11/10/2016 |
name changed to Zelira Therapeutics Limited | 05/12/2019 |
The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. | 18/11/2016 |
The company is pleased to announce that it has successfully raised the maximum allowed under its prospectus offering. A total of 160,000,000 post-consolidation shares will be issued to new investors at 2.5 cents per share raising the full $4,000,000. The funds raised are to continue with pre-clinical R&D activities, fund human clinical trials and expand the management/ advisory team. | 15/11/2016 |
The company issues a second supplementary prospectus intended to be read with the prospectus dated 11 July 2016 and the supplementary prospectus lodged 11 October 2016. | 08/11/2016 |
The company lodges its Quarterly Activities Report. | 31/10/2016 |
The company lodges its Quarterly Cashflow Report. | 31/10/2016 |
The company's meeting will be held at 12.30pm (WST) on 28 November 2016 at CPS Capital Boardroom Level 45, 108 St Georges Terrace Perth WA 6000. | 28/10/2016 |
The company advises that the ASX has granted a waiver from listing rule 14.7 to the extent necessary to permit the Company to issue securities, as approved by shareholders at the general meeting held on 25 July 2016. This is purely a technical issue related to the extended timetable and does not affect any material aspect of the transaction. | 26/10/2016 |
we understand that on or about this date the company consolidated its shares 1 for 5 | 25/10/2016 |
The share consolidation has been completed. | 12/10/2016 |
On 11 October 2016, the company lodged a supplementary prospectus with the ASIC which extends the offer period by a minimum of one month. Unfortunately, due to technical issues associated with having the company re-admitted to ASX for quotations the company is required to issue the attached supplementary prospectus and extend the offer period until no earlier than the 11 November 2016. | 12/10/2016 |
name changed from Gleneagle Gold Limited | 11/10/2016 |
Your browser may reflect a date of printing in American format.
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Osagie Imasogie | Chairman | 02/12/2019 |
| Harry Karelis | Deputy Chairman | 17/11/2016 |
| Richard Hopkins | Managing Director | 01/07/2018 |
| Lisa Gray | Director | 02/12/2019 |
| Jason Peterson | Director | 17/11/2016 |
| Oludare Odumosu | Director | 02/12/2019 |
| Tim Slate | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Stewart Washer | Non Exec Director | 17/11/2016 | 02/12/2019 |
| Mara Gordon | Director | 17/11/2016 | 02/12/2019 |
| Leon Davies | Non Exec Director | 20/04/2011 | 17/11/2016 |
| Ian Love | Director | 23/04/2010 | 17/11/2016 |
| Wayne Loxton | Director | 23/04/2010 | 17/11/2016 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.